We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




New Genetic Disease Identified in Children

By LabMedica International staff writers
Posted on 09 Apr 2014
A new genetic disease that causes neurologic, muscle, eye and liver problems in children has been identified by a combination of modern gene-sequencing techniques. More...


Mutations in the gene coding for N-glycanase 1 (NGLY1), an enzyme that recycles defective products from a cellular assembly line, was found in children who have varying degrees of movement disorders, including a characteristic combination of muscle contractions that causes abnormal tremulous movements.

Scientists at Lucile Packard Children’s Hospital (Palo Alto, CA, USA) and an international team of collaborators found eight children who through case reports and social media had clinical symptoms similar to an initial case and were found in a matter of months. All patients had global developmental delay, a movement disorder, and hypotonia. Other common findings included hypolacrima or alacrima (7/8), electroencephalography (EEG) abnormalities (7/8), elevated liver transaminases (6/7), microcephaly (6/8), abnormal brain imaging (6/8), diminished reflexes (6/8).

Exome sequencing was performed in the different collaborating laboratories using the HiSeq2000 platform (Illumina; San Diego, CA, USA) and the SureSelect Human All Exon 50 Mb Kit (Agilent; Santa Clara CA, USA) and for all patients, variants were confirmed by Sanger sequencing. The nonsense mutation c.1201A>T (p.R401X) was the most common deleterious allele identified, present in the homozygous state in five of eight cases and in the compound heterozygous state in one case. Two patients did not carry the c.1201A>T (p.R401X) mutation and their clinical phenotype was relatively mild by comparison.

The study confirmed that children with a defective NGLY1 gene do not make the N-glycanase enzyme. The scientists also observed that the children's liver biopsies contained an amorphous substance, which they suspected was an accumulation of protein that did not get recycled. Gregory Enns, MB, ChB, an associate professor of genetics in pediatrics and co-lead author, said, “This represents a complete change in the way we're going about clinical medicine. This is happening so quickly because of the integration of the families with the scientists, and because so many people are coming at this from so many angles.” The study was published on March 20, 2014, in the journal Genetics in Medicine.

Related Links:

Lucile Packard Children’s Hospital
Illumina
Agilent



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.